Related Experiment Video

Updated: Oct 12, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Recent Advances on Drugs and Vaccines for COVID-19

Fang Peng1, Hao Yuan1, Sixian Wu1

  • 187803The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, China.

Inquiry : a Journal of Medical Care Organization, Provision and Financing
|November 25, 2021
PubMed

Insights

The global Coronavirus Disease 2019 (COVID-19) situation remains severe. While vaccines offer the best hope for future infection management, early COVID-19 drugs showed limited efficacy, necessitating ongoing research.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • The global Coronavirus Disease 2019 (COVID-19) pandemic continues to pose a significant public health challenge.
  • Despite extensive research, early-stage COVID-19 specific drugs have not met therapeutic expectations.
  • Vaccines, by stimulating protective immunity, are considered the most promising strategy for managing COVID-19 infection.

Purpose of the Study:

  • To identify the latest advancements in the research and development of COVID-19 drugs and vaccines.
  • To provide a comprehensive reference for the prevention and treatment of COVID-19.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of clinical trial data for COVID-19 therapeutics and vaccines.
  • Synthesis of information on drug efficacy and vaccine effectiveness.

Main Results:

  • Significant progress has been made in vaccine development, offering a viable path towards immunity.
  • Several antiviral therapies initially highlighted have demonstrated suboptimal curative effects.
  • The landscape of COVID-19 treatment is evolving, with a continued focus on vaccine-induced immunity.

Conclusions:

  • Vaccines remain the primary strategy for controlling COVID-19 due to the limitations of current antiviral therapies.
  • Continued research and development are crucial for refining existing treatments and discovering novel therapeutic options.
  • This review serves as a reference for understanding the current state of COVID-19 drug and vaccine development.
Keywords:
COVID-19SARS-CoV-2anti-SARS-CoV-2 antibodyantiviral drugscoronavirusvaccines

More Related Videos

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.5K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.4K

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
474
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
12
Vaccinations01:51

Vaccinations

Overview
46.0K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
847
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
12
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K